CSIMarket Company Name, Ticker, Customers, else..


Zoetis Inc   (NYSE: ZTS)
Other Ticker:  
 

Zoetis Inc

ZTS's Fundamental analysis



Looking into Zoetis Inc growth rates, revenue grew by 11.02 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 1233

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.72 %

Zoetis Inc 's net income grew by 16.11 % in III. Quarter 2024 year on year, above company average,

• More on ZTS's Growth


Zoetis Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Zoetis Inc PEG ratio is at 4.08 Zoetis Inc realized cash reduction of $ -0.09 per share in trailing twelve-month period.
Company
33.46
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.83.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.


• More on ZTS's Valuation
 
 Total Debt (Millions $) 6,574
 Dividend TTM ($) 1.73 $
 Dividend Yield TTM (%) 0.98 %
 Revenue/Employee (TTM) $ 649,078
 Net Income/Employee (TTM) $ 172,908
 Receivable Turnover (TTM) 6.79
 Tangible Book Value (Per Share $) 2.88

Zoetis Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Zoetis Inc PEG ratio is at 4.08 Zoetis Inc realized cash outflow of $ -0.09per share in trailing twelve-month period.
Company
33.46
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 8.83.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.

Zoetis Inc Price to Book Ratio is at 15.44 lower than Industry Avg. of 81.16. and higher than S&P 500 Avg. of 0.01

• More on ZTS's Valuation

•  Market Capitalization (Millions $) 80,791
•  Shares Outstanding (Millions) 454
•  Employees 14,100
•  Revenues (TTM) (Millions $) 9,152
•  Net Income (TTM) (Millions $) 2,438
•  Cash Flow (TTM) (Millions $) -40
•  Capital Exp. (TTM) (Millions $) -637
•  Total Debt (Millions $) 6,574
•  Dividend TTM ($) 1.73 $
•  Dividend Yield TTM (%) 0.98 %
•  Revenue/Employee (TTM) $ 649,078
•  Net Income/Employee(TTM) $ 172,908
•  Receivable Turnover Ratio (TTM) 6.79
•  Tangible Book Value (Per Share $) 2.88

•  Market Capitalization (Millions $) 80,791
•  Shares Outstanding (Millions) 454
•  Employees 14,100
•  Revenues (TTM) (Millions $) 9,152
•  Net Income (TTM) (Millions $) 2,438
•  Cash Flow (TTM) (Millions $) -40
•  Capital Exp. (TTM) (Millions $) -637


    ZTS's Profitability Comparisons
Zoetis Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 38.32 % from 36.59 % in II. Quarter.

Zoetis Inc net profit margin of 28.98 % is currently ranking no. 16 in Major Pharmaceutical Preparations industry, ranking no. 29 in Healthcare sector and number 377 in S&P 500.


Profitability by Segment
International 68.56 %
Total 28.98 %



  Ratio
•   Capital Ratio (MRQ) 3.69
•  Total Debt to Equity (MRQ) 1.26
•  Tangible Leverage Ratio (MRQ) 7
•  Asset Turnover Ratio (TTM) 0.65
•  Inventory Turnover Ratio (TTM) 1.09



Zoetis Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 38.32 % from 36.59 % in II. Quarter.

Zoetis Inc net profit margin of 28.98 % is currently ranking no. 16 in Major Pharmaceutical Preparations industry, ranking no. 29 in Healthcare sector and number 377 in S&P 500.

• More on ZTS's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com